Ortivus AB (publ) interim report for the period April

Ortivus: – An expansive e-Health company

Highlights April – June 2022

Ortivus signed a contract for the delivery of equipment to Region Västmanland’s ambulance and hospital operations. The contract covers Ortivus MobiMed Life, semi-automatic and manual defibrillators, to an order value of 6.9 MSEK. The contract duration is 2 years with a possible extension for another 2 years.
Ortivus signed a contract for the delivery of MobiMed Life, semi-automatic external defibrillators (AED) to Region Värmland, which is a new customer for the company. The agreement applies to all 12 municipalities in the region as well as other authorities. The value of the delivery is estimated to 3.2 MSEK and the duration of the contract is 2 years with a possible extension for another 2 years.
Ortivus received marketing approval for MobiMed Monitor in Australia.
Ortivus’ long-term growth targets were communicated. The objective is an organic average growth of 15% annually with maintained profitability. Ortivus aims both to increase sales to existing customers and to take additional market shares on new geographical markets within both prehospital care and primary care.

Significant events after end of the period

Ortivus received an order covering updated hardware to the ambulance service in Northern Ireland, which has been the company’s customer since 2019. The order value is estimated to 3.2 MSEK.

April – June 2022

Net sales amounted to 26.4 (23.6) MSEK.
The gross margin amounted to 57 (49) %.
Profit after tax amounted to 3.5 (3.1) MSEK.
Earnings after tax per share before and after dilution amounted to 0.08 (0.07) SEK.
Operating cash flow before changes in working capital amounted to 8.9 (7.0) MSEK.

January – June 2022

Net sales amounted to 51.0 (47.1) MSEK.
The gross margin amounted to 53 (49) %.
Profit after tax amounted to 5.5 (4.8) MSEK.
Earnings after tax per share before and after dilution amounted to 0.12 (0.11) SEK.
Operating cash flow before changes in working capital amounted to 0.8 (1.6) MSEK.

	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Jan-Dec 2022
Net sales (MSEK)	26.4	23.6	51.0	47.1	94.3
Gross margin (%)	57%	49%	53%	49%	51%
Operating profit (MSEK)	3.5	3.2	5.5	4.9	9.3
Operating margin (%)	13%	13%	11%	10%	10%
EBITDA (MSEK)	4.4	3.5	6.8	5.5	12.7

About Ortivus

Ortivus develops and commercialises MobiMed, medical technology solutions for a safer and more efficient
healthcare. The company was founded in 1985 and is today a leading provider of mobile digital
solutions for prehospital care, worldwide. Ortivus' products are based on in-depth expertise
in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm and the company has, since 1998, a wholly-owned subsidiary based in the United Kingdom.

MobiMed is a modular platform that currently is used by over 12,000 paramedics in over 2,700 emergency vechicles. The platform consists of a monitor that in real-time measures, monitors and shares patients'
vital parameters, such as, ECG, blood pressure and blood oxygenation. The system also consists
of an electronic patient record for decision support, collection of patient data and clinical documentation.
MobiMed has a total weight of 3.5kg and is created to function in a demanding environment and out in
the field. The two-way communication supports telemedicine consulting with clinical experts while patient data is seamlessly integrated into the medical records at the hospitals and primary care centers. MobiMed saves time and helps healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

Ortivus Interim Report April June 2022

Ortivus AB (publ) interim report for the period April – June 2022